Screening and Management of Cardiovascular Risk in Belgian Women Aged > or = 65 Years With Metastatic Breast Cancer Before and After Anthracycline Treatment

The physician will be requested:

• To include 15 consecutive patients aged > or = 65 years who will be treated with anthracyclines in first and second line MBC. The physician will be encouraged to enrol 2 arms of 8 patients (one treated with liposomal and one with non-liposomal anthracyclines) for observation and comparison. Each arm will be closed as soon as 150 patients are included at a national level.
• To report their cardiovascular risk factors
• To provide the results of routinely performed cardiac evaluation before treatment
• To monitor routinely cardiovascular parameters during treatment and report them afterwards
• To monitor efficacy and tolerance of treatments, as normal practice prescribes, reported and related to the variables described in objectives
• To ensure that quality of life will be assessed with the EORTC QLQ-C30 questionnaire
• To monitor and report progression free survival and cardiac events
• To record and transmit spontaneously reported adverse events. These will be handled according to legal requirements

Follow-up will cover a period of 15 months following inclusion.

The study will have 3 visits and 2 contacts:

• One visit at entry
• One visit after 3 cycles of anthracycline containing therapy
• One visit at the end of treatment
• Contact at 9 months after inclusion
• Contact at 15 months after inclusion